Aijaz Ahmad Johna,b,c, Yeon-Suk Yanga,b,c, Jun Xiea,c,d, Sachin Chaugulea,b,c, Xu Xue, Ann-Hwee Leef, Kyoung-Mi Leeg, Kwang Hwan Parkg, Guangping Gaoa,c,d,h, and Jae-Hyuck Shima,b,c,h,1
aDepartment of Genetic and Cellular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655;
bDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01655;
cHorae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01655;
dViral Vector Core, University of Massachusetts Chan Medical School, Worcester, MA 01655;
eDivision of Surgical Sciences, Department of Surgery, Beth Israel Deaconess Medical center, Harvard Medical School, Boston, MA 02215;
fRegeneron Pharmaceuticals, Tarrytown, NY 10591;
gDepartment of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 03722, South Korea; and
hLi Weibo Institute for Rare Diseases Research, UMass Chan Medical School, Worcester, MA 01655
1To whom correspondence may be addressed.